##fileformat=VCFv4.1
##fileDate=20140506
##source=Ingenuity VA 3.0.20140417
##reference=NCBIb37
##INFO=<ID=GENE_REGION,Number=.,Type=String,Description="Gene region containing variant">
##INFO=<ID=GENE_SYMBOL,Number=.,Type=String,Description="">
##INFO=<ID=TRANSCRIPT_ID,Number=.,Type=String,Description="">
##INFO=<ID=HGVS_TRANSCRIPT,Number=.,Type=String,Description="HGVS transcript variant">
##INFO=<ID=HGVS_PROTEIN,Number=.,Type=String,Description="HGVS protein variant">
##INFO=<ID=TRANSLATION_IMPACT,Number=.,Type=String,Description="Translation impact">
##INFO=<ID=SIFT_FUNCTION,Number=.,Type=String,Description="SIFT functional prediction,Source=SIFT,Version=01/2013">
##INFO=<ID=POLYPHEN_FUNCTION,Number=.,Type=String,Description="PolyPhen-2 functional prediction,Source=Polyphen-2,Version=HumVar Training set 2011_12">
##INFO=<ID=BLOSUM50,Number=.,Type=Float,Description="BLOSUM50 biochemical conservation score">
##INFO=<ID=PHYLOP,Number=.,Type=Float,Description="PhyloP vertebrate conservation p-value,Source=PhyloP,Version=hg19 (01/2009)">
##INFO=<ID=ING_FINDINGS,Number=.,Type=Float,Description="Ingenuity variant findings,Source=Ingenuity Knowledge Base,Version=Arrakis 140408.002">
##INFO=<ID=ASSESSMENT,Number=.,Type=String,Description="Inferred assessment">
##INFO=<ID=DBSNP,Number=.,Type=String,Description="dbSNP identifiers,Source=dbSNP,Version=138">
##INFO=<ID=1000G_AF,Number=.,Type=Float,Description="1000 Genomes project allele frequency,Source=1000 Genomes,Version=3">
##INFO=<ID=ESP_AF,Number=.,Type=Float,Description="Exome Server Project allele frequency,Source=EVS,Version=v0.0.21">
##INFO=<ID=ESP_AF_AA,Number=.,Type=Float,Description="Exome Server Project African American allele frequency,Source=EVS,Version=v0.0.21">
##INFO=<ID=ESP_AF_EA,Number=.,Type=Float,Description="Exome Server Project European American allele frequency,Source=EVS,Version=v0.0.21">
##INFO=<ID=END,Number=1,Type=Integer,Description="End position of the variant described in this record">
##INFO=<ID=SVLEN,Number=.,Type=Integer,Description="Difference in length between REF and ALT alleles">
##INFO=<ID=SVTYPE,Number=1,Type=String,Description="Type of structural variant">
##FORMAT=<ID=GT,Number=1,Type=String,Description="Genotype">
##FORMAT=<ID=CQ,Number=1,Type=Integer,Description="Call Quality">
##FORMAT=<ID=DP,Number=1,Type=Integer,Description="Read Depth">
##FORMAT=<ID=AF,Number=1,Type=Integer,Description="Allele Frequency">
##FORMAT=<ID=ING_CH,Number=1,Type=String,Description="Ingenuity Inferred Compound Heterozygous">
##FORMAT=<ID=ING_IA,Number=1,Type=String,Description="Ingenuity Inferred Activity">
##FORMAT=<ID=AD,Number=G,Type=Integer,Description="Allele Depth">
#CHROM	POS	ID	REF	ALT	QUAL	FILTER	INFO	FORMAT	Case3_variants.vcf
chr4	1807894	.	G	A	100	PASS	DBSNP=7688609;1000G_AF=95.76;ESP_AF=95.51;ESP_AF_AA=86.90;ESP_AF_EA=99.92;ING_FINDINGS=1;ASSESSMENT=Benign;ING_PHENOTYPE="bladder carcinoma";TRANSCRIPT_ID=NM_000142.4;HGVS_TRANSCRIPT=c.1953G>A *;HGVS_PROTEIN=p.T651T;GENE_REGION=Exonic;GENE_SYMBOL=FGFR3;TRANSLATION_IMPACT=synonymous;BLOSUM50=5	GT:CQ:DP:AF:ING_CH:ING_IA:AD	1/1:100:2406:100:.:normal:1153,1253
chr4	1807894	.	G	A	100	PASS	DBSNP=7688609;1000G_AF=95.76;ESP_AF=95.51;ESP_AF_AA=86.90;ESP_AF_EA=99.92;ING_FINDINGS=1;ASSESSMENT=Benign;ING_PHENOTYPE="bladder carcinoma";TRANSCRIPT_ID=NM_001163213.1;HGVS_TRANSCRIPT=c.1959G>A *;HGVS_PROTEIN=p.T653T;GENE_REGION=Exonic;GENE_SYMBOL=FGFR3;TRANSLATION_IMPACT=synonymous;BLOSUM50=5	GT:CQ:DP:AF:ING_CH:ING_IA:AD	1/1:100:2406:100:.:normal:976,1430
chr4	1807894	.	G	A	100	PASS	DBSNP=7688609;1000G_AF=95.76;ESP_AF=95.51;ESP_AF_AA=86.90;ESP_AF_EA=99.92;ING_FINDINGS=1;ASSESSMENT=Benign;ING_PHENOTYPE="bladder carcinoma";TRANSCRIPT_ID=NM_022965.3;HGVS_TRANSCRIPT=c.1617G>A *;HGVS_PROTEIN=p.T539T;GENE_REGION=Exonic;GENE_SYMBOL=FGFR3;TRANSLATION_IMPACT=synonymous;BLOSUM50=5	GT:CQ:DP:AF:ING_CH:ING_IA:AD	1/1:100:2406:100:.:normal:649,1757
chr4	55141055	.	A	G	85	PASS	DBSNP=1873778;1000G_AF=96.34;ESP_AF=95.89;ESP_AF_AA=88.15;ESP_AF_EA=99.85;ING_FINDINGS=8;ASSESSMENT=Benign;ING_PHENOTYPE="gastrointestinal stromal tumor";TRANSCRIPT_ID=NM_006206.4;HGVS_TRANSCRIPT=c.1701A>G;HGVS_PROTEIN=p.P567P;GENE_REGION=Exonic;GENE_SYMBOL=PDGFRA;TRANSLATION_IMPACT=synonymous;BLOSUM50=10	GT:CQ:DP:AF:ING_CH:ING_IA:AD	1/1:85:1197:100:.:normal:253,944
chr4	55972974	.	T	A	53	PASS	DBSNP=1870377;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;1000G_AF=23.61;ESP_AF=19.39;ESP_AF_AA=11.01;ESP_AF_EA=23.69;ING_FINDINGS=9;ASSESSMENT=Benign;ING_PHENOTYPE="non small cell lung adenocarcinoma";TRANSCRIPT_ID=NM_002253.2;HGVS_TRANSCRIPT=c.1416A>T;HGVS_PROTEIN=p.Q472H;GENE_REGION=Exonic;GENE_SYMBOL=KDR;TRANSLATION_IMPACT=missense;BLOSUM50=1	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:53:2065:57:.:gain:1376,689
chr5	112175770	.	G	A	53	PASS	DBSNP=41115;1000G_AF=66.18;ESP_AF=58.62;ESP_AF_AA=52.66;ESP_AF_EA=61.67;ING_FINDINGS=13;ASSESSMENT=Benign;ING_PHENOTYPE="adenomatous polyposis coli";TRANSCRIPT_ID=NM_001127510.2;HGVS_TRANSCRIPT=c.4479G>A;HGVS_PROTEIN=p.T1493T;GENE_REGION=Exonic;GENE_SYMBOL=APC;TRANSLATION_IMPACT=synonymous;BLOSUM50=5	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:53:2477:28:.:normal:1745,732
chr5	112175770	.	G	A	53	PASS	DBSNP=41115;1000G_AF=66.18;ESP_AF=58.62;ESP_AF_AA=52.66;ESP_AF_EA=61.67;ING_FINDINGS=13;ASSESSMENT=Benign;ING_PHENOTYPE="adenomatous polyposis coli";TRANSCRIPT_ID=NM_000038.5;HGVS_TRANSCRIPT=c.4479G>A;HGVS_PROTEIN=p.T1493T;GENE_REGION=Exonic;GENE_SYMBOL=APC;TRANSLATION_IMPACT=synonymous;BLOSUM50=5	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:53:2477:28:.:normal:1761,716
chr5	112175770	.	G	A	53	PASS	DBSNP=41115;1000G_AF=66.18;ESP_AF=58.62;ESP_AF_AA=52.66;ESP_AF_EA=61.67;ING_FINDINGS=13;ASSESSMENT=Benign;ING_PHENOTYPE="adenomatous polyposis coli";TRANSCRIPT_ID=NM_001127511.2;HGVS_TRANSCRIPT=c.4425G>A;HGVS_PROTEIN=p.T1475T;GENE_REGION=Exonic;GENE_SYMBOL=APC;TRANSLATION_IMPACT=synonymous;BLOSUM50=5	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:53:2477:28:.:normal:2163,314
chr5	149433596	.	T	G	80	PASS	DBSNP=2066934;1000G_AF=72.75;ESP_AF=48.08;ESP_AF_AA=62.26;ESP_AF_EA=40.81;ASSESSMENT=Benign;ING_PHENOTYPE="familial progressive subcortical gliosis";TRANSCRIPT_ID=NM_001288705.1;HGVS_TRANSCRIPT=c.*36A>C;GENE_REGION=3'UTR;GENE_SYMBOL=CSF1R	GT:CQ:DP:AF:ING_CH:ING_IA:AD	1/1:80:766:100:.:normal:193,573
chr5	149433596	.	T	G	80	PASS	DBSNP=2066934;1000G_AF=72.75;ESP_AF=48.08;ESP_AF_AA=62.26;ESP_AF_EA=40.81;ASSESSMENT=Benign;ING_PHENOTYPE="familial progressive subcortical gliosis";TRANSCRIPT_ID=NR_109969.1;GENE_REGION=ncRNA;GENE_SYMBOL=CSF1R	GT:CQ:DP:AF:ING_CH:ING_IA:AD	1/1:80:766:100:.:normal:350,416
chr5	149433596	.	T	G	80	PASS	DBSNP=2066934;1000G_AF=72.75;ESP_AF=48.08;ESP_AF_AA=62.26;ESP_AF_EA=40.81;ASSESSMENT=Benign;ING_PHENOTYPE="familial progressive subcortical gliosis";TRANSCRIPT_ID=NM_005211.3;HGVS_TRANSCRIPT=c.*36A>C;GENE_REGION=3'UTR;GENE_SYMBOL=CSF1R	GT:CQ:DP:AF:ING_CH:ING_IA:AD	1/1:80:766:100:.:normal:197,569
chr5	149433597	.	G	A	81	PASS	DBSNP=2066933;1000G_AF=70.36;ESP_AF=49.59;ESP_AF_AA=64.16;ESP_AF_EA=42.13;ASSESSMENT=Benign;ING_PHENOTYPE="familial progressive subcortical gliosis";TRANSCRIPT_ID=NM_001288705.1;HGVS_TRANSCRIPT=c.*35C>T;GENE_REGION=3'UTR;GENE_SYMBOL=CSF1R	GT:CQ:DP:AF:ING_CH:ING_IA:AD	1/1:81:789:99:.:normal:188,601
chr5	149433597	.	G	A	81	PASS	DBSNP=2066933;1000G_AF=70.36;ESP_AF=49.59;ESP_AF_AA=64.16;ESP_AF_EA=42.13;ASSESSMENT=Benign;ING_PHENOTYPE="familial progressive subcortical gliosis";TRANSCRIPT_ID=NR_109969.1;GENE_REGION=ncRNA;GENE_SYMBOL=CSF1R	GT:CQ:DP:AF:ING_CH:ING_IA:AD	1/1:81:789:99:.:normal:229,560
chr5	149433597	.	G	A	81	PASS	DBSNP=2066933;1000G_AF=70.36;ESP_AF=49.59;ESP_AF_AA=64.16;ESP_AF_EA=42.13;ASSESSMENT=Benign;ING_PHENOTYPE="familial progressive subcortical gliosis";TRANSCRIPT_ID=NM_005211.3;HGVS_TRANSCRIPT=c.*35C>T;GENE_REGION=3'UTR;GENE_SYMBOL=CSF1R	GT:CQ:DP:AF:ING_CH:ING_IA:AD	1/1:81:789:99:.:normal:316,473
chr7	55249063	.	G	A	44	PASS	DBSNP=1050171;PHYLOP=5.649E-4;1000G_AF=41.87;ESP_AF=54.24;ESP_AF_AA=42.26;ESP_AF_EA=60.38;ING_FINDINGS=14;ASSESSMENT=Benign;ING_PHENOTYPE="non small cell lung adenocarcinoma";TRANSCRIPT_ID=NR_047551.1;GENE_REGION=ncRNA;GENE_SYMBOL=EGFR-AS1	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:44:1179:69:.:normal:737,442
chr7	55249063	.	G	A	44	PASS	DBSNP=1050171;PHYLOP=5.649E-4;1000G_AF=41.87;ESP_AF=54.24;ESP_AF_AA=42.26;ESP_AF_EA=60.38;ING_FINDINGS=14;ASSESSMENT=Benign;ING_PHENOTYPE="non small cell lung adenocarcinoma";TRANSCRIPT_ID=NM_005228.3;HGVS_TRANSCRIPT=c.2361G>A;HGVS_PROTEIN=p.Q787Q;GENE_REGION=Exonic;GENE_SYMBOL=EGFR;TRANSLATION_IMPACT=synonymous;BLOSUM50=7	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:44:1179:69:.:normal:850,329
chr9	21970985	.	C	T	43	PASS	SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;ESP_AF=0.00;ESP_AF_AA=0.00;ESP_AF_EA=0.00;ING_FINDINGS=2;ASSESSMENT="Likely Benign";ING_PHENOTYPE="malignant cutaneous melanoma cancer";TRANSCRIPT_ID=NM_058197.4;HGVS_TRANSCRIPT=c.*296G>A;GENE_REGION=3'UTR;GENE_SYMBOL=CDKN2A	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:43:864:52:.:normal:607,257
chr9	21970985	.	C	T	43	PASS	SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;ESP_AF=0.00;ESP_AF_AA=0.00;ESP_AF_EA=0.00;ING_FINDINGS=2;ASSESSMENT="Likely Benign";ING_PHENOTYPE="malignant cutaneous melanoma cancer";TRANSCRIPT_ID=NM_000077.4;HGVS_TRANSCRIPT=c.373G>A;HGVS_PROTEIN=p.D125N;GENE_REGION=Exonic;GENE_SYMBOL=CDKN2A;TRANSLATION_IMPACT=missense;BLOSUM50=2	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:43:864:52:.:normal:533,331
chr9	21970985	.	C	T	43	PASS	SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;ESP_AF=0.00;ESP_AF_AA=0.00;ESP_AF_EA=0.00;ING_FINDINGS=2;ASSESSMENT="Likely Benign";ING_PHENOTYPE="malignant cutaneous melanoma cancer";TRANSCRIPT_ID=NM_001195132.1;HGVS_TRANSCRIPT=c.373G>A;HGVS_PROTEIN=p.D125N;GENE_REGION=Exonic;GENE_SYMBOL=CDKN2A;TRANSLATION_IMPACT=missense;BLOSUM50=2	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:43:864:52:.:normal:692,172
chr9	21970985	.	C	T	43	PASS	SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;ESP_AF=0.00;ESP_AF_AA=0.00;ESP_AF_EA=0.00;ING_FINDINGS=2;ASSESSMENT="Likely Benign";ING_PHENOTYPE="malignant cutaneous melanoma cancer";TRANSCRIPT_ID=NM_058195.3;HGVS_TRANSCRIPT=c.*17G>A;GENE_REGION=3'UTR;GENE_SYMBOL=CDKN2A	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:43:864:52:.:normal:665,199
chr9	21971000	.	C	A	45	PASS	PHYLOP=2.153E-3;ESP_AF=0.00;ESP_AF_AA=0.00;ESP_AF_EA=0.00;ING_FINDINGS=11;ASSESSMENT=Pathogenic;ING_PHENOTYPE="malignant cutaneous melanoma cancer";TRANSCRIPT_ID=NM_058197.4;HGVS_TRANSCRIPT=c.*281G>T;GENE_REGION=3'UTR;GENE_SYMBOL=CDKN2A	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:45:869:52:.:loss:770,99
chr9	21971000	.	C	A	45	PASS	PHYLOP=2.153E-3;ESP_AF=0.00;ESP_AF_AA=0.00;ESP_AF_EA=0.00;ING_FINDINGS=11;ASSESSMENT=Pathogenic;ING_PHENOTYPE="malignant cutaneous melanoma cancer";TRANSCRIPT_ID=NM_000077.4;HGVS_TRANSCRIPT=c.358G>T;HGVS_PROTEIN=p.E120*;GENE_REGION=Exonic;GENE_SYMBOL=CDKN2A;TRANSLATION_IMPACT="stop gain"	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:45:869:52:.:loss:498,371
chr9	21971000	.	C	A	45	PASS	PHYLOP=2.153E-3;ESP_AF=0.00;ESP_AF_AA=0.00;ESP_AF_EA=0.00;ING_FINDINGS=11;ASSESSMENT=Pathogenic;ING_PHENOTYPE="malignant cutaneous melanoma cancer";TRANSCRIPT_ID=NM_001195132.1;HGVS_TRANSCRIPT=c.358G>T;HGVS_PROTEIN=p.E120*;GENE_REGION=Exonic;GENE_SYMBOL=CDKN2A;TRANSLATION_IMPACT="stop gain"	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:45:869:52:.:loss:526,343
chr9	21971000	.	C	A	45	PASS	PHYLOP=2.153E-3;ESP_AF=0.00;ESP_AF_AA=0.00;ESP_AF_EA=0.00;ING_FINDINGS=11;ASSESSMENT=Pathogenic;ING_PHENOTYPE="malignant cutaneous melanoma cancer";TRANSCRIPT_ID=NM_058195.3;HGVS_TRANSCRIPT=c.*2G>T;GENE_REGION=3'UTR;GENE_SYMBOL=CDKN2A	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:45:869:52:.:loss:708,161
chr10	43613843	.	G	T	100	PASS	DBSNP=1800861;1000G_AF=72.35;ESP_AF=80.26;ESP_AF_AA=87.54;ESP_AF_EA=76.53;ING_FINDINGS=89;ASSESSMENT=Benign;ING_PHENOTYPE="multiple endocrine neoplasia type 2A";TRANSCRIPT_ID=NM_020630.4;HGVS_TRANSCRIPT=c.2307G>T *;HGVS_PROTEIN=p.L769L;GENE_REGION=Exonic;GENE_SYMBOL=RET;TRANSLATION_IMPACT=synonymous;BLOSUM50=5	GT:CQ:DP:AF:ING_CH:ING_IA:AD	1/1:100:3199:100:.:normal:767,2432
chr10	43613843	.	G	T	100	PASS	DBSNP=1800861;1000G_AF=72.35;ESP_AF=80.26;ESP_AF_AA=87.54;ESP_AF_EA=76.53;ING_FINDINGS=89;ASSESSMENT=Benign;ING_PHENOTYPE="multiple endocrine neoplasia type 2A";TRANSCRIPT_ID=NM_020975.4;HGVS_TRANSCRIPT=c.2307G>T *;HGVS_PROTEIN=p.L769L;GENE_REGION=Exonic;GENE_SYMBOL=RET;TRANSLATION_IMPACT=synonymous;BLOSUM50=5	GT:CQ:DP:AF:ING_CH:ING_IA:AD	1/1:100:3199:100:.:normal:940,2259
chr10	43615633	.	C	G	100	PASS	DBSNP=1800863;1000G_AF=16.01;ESP_AF=16.10;ESP_AF_AA=11.10;ESP_AF_EA=18.66;ING_FINDINGS=76;ASSESSMENT=Benign;ING_PHENOTYPE="multiple endocrine neoplasia type 2A";TRANSCRIPT_ID=NM_020630.4;HGVS_TRANSCRIPT=c.2712C>G;HGVS_PROTEIN=p.S904S;GENE_REGION=Exonic;GENE_SYMBOL=RET;TRANSLATION_IMPACT=synonymous;BLOSUM50=5	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:100:1396:49:.:normal:937,459
chr10	43615633	.	C	G	100	PASS	DBSNP=1800863;1000G_AF=16.01;ESP_AF=16.10;ESP_AF_AA=11.10;ESP_AF_EA=18.66;ING_FINDINGS=76;ASSESSMENT=Benign;ING_PHENOTYPE="multiple endocrine neoplasia type 2A";TRANSCRIPT_ID=NM_020975.4;HGVS_TRANSCRIPT=c.2712C>G;HGVS_PROTEIN=p.S904S;GENE_REGION=Exonic;GENE_SYMBOL=RET;TRANSLATION_IMPACT=synonymous;BLOSUM50=5	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:100:1396:49:.:normal:1203,193
chr11	534242	.	A	G	100	PASS	DBSNP=12628;1000G_AF=29.83;ESP_AF=35.45;ESP_AF_AA=37.49;ESP_AF_EA=34.41;ING_FINDINGS=9;ASSESSMENT=Benign;ING_PHENOTYPE="Costello syndrome";TRANSCRIPT_ID=NM_001130442.1;HGVS_TRANSCRIPT=c.81T>C;HGVS_PROTEIN=p.H27H;GENE_REGION=Exonic;GENE_SYMBOL=HRAS;TRANSLATION_IMPACT=synonymous;BLOSUM50=10	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:100:2206:59:.:normal:1470,736
chr11	534242	.	A	G	100	PASS	DBSNP=12628;1000G_AF=29.83;ESP_AF=35.45;ESP_AF_AA=37.49;ESP_AF_EA=34.41;ING_FINDINGS=9;ASSESSMENT=Benign;ING_PHENOTYPE="Costello syndrome";TRANSCRIPT_ID=NM_005343.2;HGVS_TRANSCRIPT=c.81T>C;HGVS_PROTEIN=p.H27H;GENE_REGION=Exonic;GENE_SYMBOL=HRAS;TRANSLATION_IMPACT=synonymous;BLOSUM50=10	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:100:2206:59:.:normal:1645,561
chr11	534242	.	A	G	100	PASS	DBSNP=12628;1000G_AF=29.83;ESP_AF=35.45;ESP_AF_AA=37.49;ESP_AF_EA=34.41;ING_FINDINGS=9;ASSESSMENT=Benign;ING_PHENOTYPE="Costello syndrome";TRANSCRIPT_ID=NM_176795.3;HGVS_TRANSCRIPT=c.81T>C;HGVS_PROTEIN=p.H27H;GENE_REGION=Exonic;GENE_SYMBOL=HRAS;TRANSLATION_IMPACT=synonymous;BLOSUM50=10	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:100:2206:59:.:normal:1726,480
chr11	108225575	.	C	T	46	PASS	PHYLOP=2.009E-3;ESP_AF=0.00;ESP_AF_AA=0.00;ESP_AF_EA=0.00;ASSESSMENT=Pathogenic;ING_PHENOTYPE=ataxia-telangiectasia;TRANSCRIPT_ID=NM_000051.3;HGVS_TRANSCRIPT=c.8824C>T;HGVS_PROTEIN=p.Q2942*;GENE_REGION=Exonic;GENE_SYMBOL=ATM;TRANSLATION_IMPACT="stop gain"	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1702:25:.:loss:1097,605
chr12	25398285	.	C	A	50	PASS	DBSNP=121913530;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION="Probably Damaging";PHYLOP=1.374E-6;ESP_AF=0.00;ESP_AF_AA=0.00;ESP_AF_EA=0.00;ING_FINDINGS=1040;ASSESSMENT="Likely Pathogenic";ING_PHENOTYPE="colorectal cancer";TRANSCRIPT_ID=NM_004985.3;HGVS_TRANSCRIPT=c.34G>T;HGVS_PROTEIN=p.G12C;GENE_REGION=Exonic;GENE_SYMBOL=KRAS;TRANSLATION_IMPACT=missense;BLOSUM50=-3	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:50:1535:47:.:gain:1076,459
chr12	25398285	.	C	A	50	PASS	DBSNP=121913530;SIFT_FUNCTION=Damaging;POLYPHEN_FUNCTION="Probably Damaging";PHYLOP=1.374E-6;ESP_AF=0.00;ESP_AF_AA=0.00;ESP_AF_EA=0.00;ING_FINDINGS=1040;ASSESSMENT="Likely Pathogenic";ING_PHENOTYPE="colorectal cancer";TRANSCRIPT_ID=NM_033360.2;HGVS_TRANSCRIPT=c.34G>T;HGVS_PROTEIN=p.G12C;GENE_REGION=Exonic;GENE_SYMBOL=KRAS;TRANSLATION_IMPACT=missense;BLOSUM50=-3	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:50:1535:47:.:gain:1291,244
chr13	28602292	.	T	C	48	PASS	DBSNP=75580865;1000G_AF=3.98;ESP_AF=5.53;ESP_AF_AA=1.36;ESP_AF_EA=7.66;ASSESSMENT=Benign;ING_PHENOTYPE="acute myeloid leukemia";TRANSCRIPT_ID=NM_004119.2;HGVS_TRANSCRIPT=c.2053+23A>G;GENE_REGION=Intronic;GENE_SYMBOL=FLT3	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:48:2019:52:.:normal:1452,567
chr13	28610183	.	A	G	100	PASS	DBSNP=2491231;1000G_AF=61.99;ESP_AF=61.64;ESP_AF_AA=29.30;ESP_AF_EA=78.21;ASSESSMENT=Benign;ING_PHENOTYPE="acute myeloid leukemia";TRANSCRIPT_ID=NM_004119.2;HGVS_TRANSCRIPT=c.1310-3T>C;GENE_REGION=Intronic;GENE_SYMBOL=FLT3	GT:CQ:DP:AF:ING_CH:ING_IA:AD	1/1:100:3638:100:.:normal:1751,1887
chr17	7579472	.	G	C	46	PASS	DBSNP=1042522;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=4.898E-4;1000G_AF=60.32;ESP_AF=63.00;ESP_AF_AA=40.51;ESP_AF_EA=74.52;ING_FINDINGS=84;ASSESSMENT=Benign;ING_PHENOTYPE="squamous-cell carcinoma";TRANSCRIPT_ID=NM_001126114.2;HGVS_TRANSCRIPT=c.215C>G;HGVS_PROTEIN=p.P72R;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=missense;BLOSUM50=-3	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1062:91:.:normal:916,146
chr17	7579472	.	G	C	46	PASS	DBSNP=1042522;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=4.898E-4;1000G_AF=60.32;ESP_AF=63.00;ESP_AF_AA=40.51;ESP_AF_EA=74.52;ING_FINDINGS=84;ASSESSMENT=Benign;ING_PHENOTYPE="squamous-cell carcinoma";TRANSCRIPT_ID=NM_001276761.1;HGVS_TRANSCRIPT=c.98C>G;HGVS_PROTEIN=p.P33R;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=missense;BLOSUM50=-3	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1062:91:.:normal:854,208
chr17	7579472	.	G	C	46	PASS	DBSNP=1042522;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=4.898E-4;1000G_AF=60.32;ESP_AF=63.00;ESP_AF_AA=40.51;ESP_AF_EA=74.52;ING_FINDINGS=84;ASSESSMENT=Benign;ING_PHENOTYPE="squamous-cell carcinoma";TRANSCRIPT_ID=NM_001126115.1;HGVS_TRANSCRIPT=c.-939C>G;GENE_REGION=Promoter;GENE_SYMBOL=TP53	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1062:91:.:normal:637,425
chr17	7579472	.	G	C	46	PASS	DBSNP=1042522;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=4.898E-4;1000G_AF=60.32;ESP_AF=63.00;ESP_AF_AA=40.51;ESP_AF_EA=74.52;ING_FINDINGS=84;ASSESSMENT=Benign;ING_PHENOTYPE="squamous-cell carcinoma";TRANSCRIPT_ID=NM_001276695.1;HGVS_TRANSCRIPT=c.98C>G;HGVS_PROTEIN=p.P33R;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=missense;BLOSUM50=-3	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1062:91:.:normal:858,204
chr17	7579472	.	G	C	46	PASS	DBSNP=1042522;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=4.898E-4;1000G_AF=60.32;ESP_AF=63.00;ESP_AF_AA=40.51;ESP_AF_EA=74.52;ING_FINDINGS=84;ASSESSMENT=Benign;ING_PHENOTYPE="squamous-cell carcinoma";TRANSCRIPT_ID=NM_001276696.1;HGVS_TRANSCRIPT=c.98C>G;HGVS_PROTEIN=p.P33R;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=missense;BLOSUM50=-3	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1062:91:.:normal:696,366
chr17	7579472	.	G	C	46	PASS	DBSNP=1042522;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=4.898E-4;1000G_AF=60.32;ESP_AF=63.00;ESP_AF_AA=40.51;ESP_AF_EA=74.52;ING_FINDINGS=84;ASSESSMENT=Benign;ING_PHENOTYPE="squamous-cell carcinoma";TRANSCRIPT_ID=NM_001126116.1;HGVS_TRANSCRIPT=c.-939C>G;GENE_REGION=Promoter;GENE_SYMBOL=TP53	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1062:91:.:normal:660,402
chr17	7579472	.	G	C	46	PASS	DBSNP=1042522;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=4.898E-4;1000G_AF=60.32;ESP_AF=63.00;ESP_AF_AA=40.51;ESP_AF_EA=74.52;ING_FINDINGS=84;ASSESSMENT=Benign;ING_PHENOTYPE="squamous-cell carcinoma";TRANSCRIPT_ID=NM_001276760.1;HGVS_TRANSCRIPT=c.98C>G;HGVS_PROTEIN=p.P33R;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=missense;BLOSUM50=-3	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1062:91:.:normal:809,253
chr17	7579472	.	G	C	46	PASS	DBSNP=1042522;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=4.898E-4;1000G_AF=60.32;ESP_AF=63.00;ESP_AF_AA=40.51;ESP_AF_EA=74.52;ING_FINDINGS=84;ASSESSMENT=Benign;ING_PHENOTYPE="squamous-cell carcinoma";TRANSCRIPT_ID=NM_001126118.1;HGVS_TRANSCRIPT=c.98C>G;HGVS_PROTEIN=p.P33R;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=missense;BLOSUM50=-3	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1062:91:.:normal:842,220
chr17	7579472	.	G	C	46	PASS	DBSNP=1042522;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=4.898E-4;1000G_AF=60.32;ESP_AF=63.00;ESP_AF_AA=40.51;ESP_AF_EA=74.52;ING_FINDINGS=84;ASSESSMENT=Benign;ING_PHENOTYPE="squamous-cell carcinoma";TRANSCRIPT_ID=NM_001276697.1;HGVS_TRANSCRIPT=c.-1020C>G;GENE_REGION=Promoter;GENE_SYMBOL=TP53	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1062:91:.:normal:780,282
chr17	7579472	.	G	C	46	PASS	DBSNP=1042522;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=4.898E-4;1000G_AF=60.32;ESP_AF=63.00;ESP_AF_AA=40.51;ESP_AF_EA=74.52;ING_FINDINGS=84;ASSESSMENT=Benign;ING_PHENOTYPE="squamous-cell carcinoma";TRANSCRIPT_ID=NM_000546.5;HGVS_TRANSCRIPT=c.215C>G;HGVS_PROTEIN=p.P72R;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=missense;BLOSUM50=-3	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1062:91:.:normal:613,449
chr17	7579472	.	G	C	46	PASS	DBSNP=1042522;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=4.898E-4;1000G_AF=60.32;ESP_AF=63.00;ESP_AF_AA=40.51;ESP_AF_EA=74.52;ING_FINDINGS=84;ASSESSMENT=Benign;ING_PHENOTYPE="squamous-cell carcinoma";TRANSCRIPT_ID=NM_001126113.2;HGVS_TRANSCRIPT=c.215C>G;HGVS_PROTEIN=p.P72R;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=missense;BLOSUM50=-3	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1062:91:.:normal:709,353
chr17	7579472	.	G	C	46	PASS	DBSNP=1042522;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=4.898E-4;1000G_AF=60.32;ESP_AF=63.00;ESP_AF_AA=40.51;ESP_AF_EA=74.52;ING_FINDINGS=84;ASSESSMENT=Benign;ING_PHENOTYPE="squamous-cell carcinoma";TRANSCRIPT_ID=NM_001276699.1;HGVS_TRANSCRIPT=c.-1020C>G;GENE_REGION=Promoter;GENE_SYMBOL=TP53	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1062:91:.:normal:616,446
chr17	7579472	.	G	C	46	PASS	DBSNP=1042522;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=4.898E-4;1000G_AF=60.32;ESP_AF=63.00;ESP_AF_AA=40.51;ESP_AF_EA=74.52;ING_FINDINGS=84;ASSESSMENT=Benign;ING_PHENOTYPE="squamous-cell carcinoma";TRANSCRIPT_ID=NM_001276698.1;HGVS_TRANSCRIPT=c.-1020C>G;GENE_REGION=Promoter;GENE_SYMBOL=TP53	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1062:91:.:normal:721,341
chr17	7579472	.	G	C	46	PASS	DBSNP=1042522;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=4.898E-4;1000G_AF=60.32;ESP_AF=63.00;ESP_AF_AA=40.51;ESP_AF_EA=74.52;ING_FINDINGS=84;ASSESSMENT=Benign;ING_PHENOTYPE="squamous-cell carcinoma";TRANSCRIPT_ID=NM_001126112.2;HGVS_TRANSCRIPT=c.215C>G;HGVS_PROTEIN=p.P72R;GENE_REGION=Exonic;GENE_SYMBOL=TP53;TRANSLATION_IMPACT=missense;BLOSUM50=-3	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1062:91:.:normal:754,308
chr17	7579472	.	G	C	46	PASS	DBSNP=1042522;SIFT_FUNCTION=Tolerated;POLYPHEN_FUNCTION=Benign;PHYLOP=4.898E-4;1000G_AF=60.32;ESP_AF=63.00;ESP_AF_AA=40.51;ESP_AF_EA=74.52;ING_FINDINGS=84;ASSESSMENT=Benign;ING_PHENOTYPE="squamous-cell carcinoma";TRANSCRIPT_ID=NM_001126117.1;HGVS_TRANSCRIPT=c.-939C>G;GENE_REGION=Promoter;GENE_SYMBOL=TP53	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:46:1062:91:.:normal:943,119
chr22	24176287	.	G	A	53	PASS	DBSNP=5030613;1000G_AF=11.11;ESP_AF=12.72;ESP_AF_AA=12.50;ESP_AF_EA=12.84;ING_FINDINGS=3;ASSESSMENT=Benign;ING_PHENOTYPE="teratoid rhabdoid tumor";TRANSCRIPT_ID=NM_003073.3;HGVS_TRANSCRIPT=c.1119-41G>A;GENE_REGION=Intronic;GENE_SYMBOL=SMARCB1	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:53:1453:60:.:normal:1048,405
chr22	24176287	.	G	A	53	PASS	DBSNP=5030613;1000G_AF=11.11;ESP_AF=12.72;ESP_AF_AA=12.50;ESP_AF_EA=12.84;ING_FINDINGS=3;ASSESSMENT=Benign;ING_PHENOTYPE="teratoid rhabdoid tumor";TRANSCRIPT_ID=NM_001007468.1;HGVS_TRANSCRIPT=c.1092-41G>A;GENE_REGION=Intronic;GENE_SYMBOL=SMARCB1	GT:CQ:DP:AF:ING_CH:ING_IA:AD	0/1:53:1453:60:.:normal:859,594

